An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Daiichi Sankyo Provides Update on Patent Dispute With Seagen
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Daiichi Sankyo Co., Ltd. announced that a jury found its drug ENHERTU® infringes Seagen's US patent 10,808,039, awarding Seagen $41.82 million in damages. The U.S. Patent Office is reviewing this patent after Daiichi Sankyo contested its validity. The court has not ruled on Seagen's request for additional royalties on future ENHERTU® sales until the patent's expiry in 2024. Daiichi Sankyo is committed to appealing the verdict and exploring options regarding the jury's decision.
Positive
Daiichi Sankyo plans to appeal the jury verdict, indicating confidence in its case.
The U.S. Patent Office is reviewing the initial granting of Seagen's patent, which may favor Daiichi Sankyo.
Negative
Daiichi Sankyo was ordered to pay $41.82 million in damages due to patent infringement.
Seagen has requested future royalty payments, which could impact Daiichi Sankyo's revenue until 2024.
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--
Daiichi Sankyo Co., Ltd. (TSE: 4568) announced today that a jury in the U.S. District Court of Eastern District of Texas decided that ENHERTU® infringes Seagen’s US patent 10,808,039 (the ’039 patent). However, on April 7, 2022, the U.S. Patent Office initiated post-grant review of the ’039 patent to determine whether the claims of that patent should not have originally been granted.
Discovered by Daiichi Sankyo, ENHERTU® is being co-developed and co-commercialized by Daiichi Sankyo and AstraZeneca.
“Daiichi Sankyo disagrees with the jury verdict, is committed to defending its rights, and will explore options with respect to the jury verdict, including post-trial motions and an appeal,” said Naoto Tsukaguchi, Corporate Officer and General Counsel, Daiichi Sankyo Co., Ltd. “We are pleased that the U.S. Patent Office has agreed to review their initial granting of the ’039 patent.”
The jury awarded Seagen $41,820,000 in damages for the period leading up to trial and found that there was willful infringement of the ’039 patent. Seagen has also requested the Court to issue an order requiring the payment of royalties on future sales of ENHERTU® until the expiration of the ’039 patent in 2024. The court has not yet ruled on Seagen’s request for royalties on future sales and whether to enhance damages in view of the jury finding of willful infringement.
On October 19, 2020, Seagen filed a complaint against Daiichi Sankyo Co., Ltd. in the U.S. District Court for the Eastern District of Texas alleging infringement of the ’039 patent covering certain antibody drug conjugates. On December 23, 2020, Daiichi Sankyo filed a petition with the U.S. Patent Office for post-grant review contesting the patentability of certain claims within the ’039 patent.
About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit: www.daiichisankyo.com.
